Cargando…

Longitudinal Aspects of VITT

In hundreds of patients worldwide, vaccination against COVID-19 with adenovirus vector vaccines (ChAdOx1 nCoV-19; Ad26.COV2.S) triggered platelet-activating anti-platelet factor 4 (PF4) antibodies inducing vaccine-induced immune thrombotic thrombocytopenia (VITT). In most VITT patients, platelet-act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schönborn, Linda, Greinacher, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898788/ https://www.ncbi.nlm.nih.gov/pubmed/35512899 http://dx.doi.org/10.1053/j.seminhematol.2022.03.001

Ejemplares similares

Decline in Pathogenic Antibodies over Time in VITT
por: Schönborn, Linda, et al.
Publicado: (2021)

SARS-CoV-2 Infection in Patients with a History of VITT
por: Schönborn, Linda, et al.
Publicado: (2022)

Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)—Insights from Clinical Cases, In Vitro Studies and Murine Models
por: Dabbiru, Venkata A. S., et al.
Publicado: (2023)

Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Greinacher, Andreas, et al.
Publicado: (2022)

Vaccine‐induced immune thrombotic thrombocytopenia (VITT) after SARS‐CoV‐2 vaccination: Two cases from Germany with unusual presentation
por: Edmonds, Rhea, et al.
Publicado: (2023)

Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy
por: Greinacher, Andreas, et al.
Publicado: (2021)

Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway
por: Salih, Farid, et al.
Publicado: (2022)

A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination
por: Handtke, Stefan, et al.
Publicado: (2021)

Epidemiology of VITT
por: Pai, Menaka
Publicado: (2022)

Vaccine‐induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources
por: Greinacher, Andreas, et al.
Publicado: (2022)

Risk of Blood Bag Lesions Induced by Standard Transfusion Devices
por: Raster, Johannes, et al.
Publicado: (2022)

The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies
por: Vayne, Caroline, et al.
Publicado: (2022)

Heparin or nonheparin anticoagulants for VITT
por: Arnold, Donald M.
Publicado: (2022)

Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021)

Understanding VITT(ual) reality
por: Rauova, Lubica, et al.
Publicado: (2021)

ViTT: Vision Transformer Tracker
por: Zhu, Xiaoning, et al.
Publicado: (2021)

Second-dose VITT: rare but real
por: Pavord, Sue, et al.
Publicado: (2022)

COVID-19 vaccin et VITT
por: Pernod, G.
Publicado: (2021)

COVID-19 and VITT: same or different?
por: Arepally, Gowthami M.
Publicado: (2021)

Long VITT: A case report
por: Roberge, Guillaume, et al.
Publicado: (2023)

Vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Warkentin, Theodore E.
Publicado: (2022)

Vaccination-induced thrombocytopenia and thrombosis (VITT) and pre-VITT: Do not miss (or misdiagnose) the new member of the thrombotic thrombocytopenias family
por: Noyé, Mickaël, et al.
Publicado: (2022)

Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
por: Kanack, Adam J., et al.
Publicado: (2022)

Understanding vaccine‐induced thrombotic thrombocytopenia (VITT)
por: Dix, Caroline, et al.
Publicado: (2022)

VITT and Second Doses of Covid-19 Vaccine
por: Lacy, Joanne, et al.
Publicado: (2021)

Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)
por: Makris, Michael, et al.
Publicado: (2021)

VITT(al) insights into vaccine-related clots
por: Strich, Jeffrey R., et al.
Publicado: (2021)

Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Gabarin, Nadia, et al.
Publicado: (2022)

Syndrome VITT : le vaccin Janssen également concerné ?
por: Manus, Jean-Marie
Publicado: (2021)

COVID-19 vaccine-induced VITT/TSS in Malaysia
Publicado: (2022)

Vaccine-induced thrombosis and thrombocytopenia (VITT); Exploring the unknown
por: Sunder, Ashok, et al.
Publicado: (2022)

Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis
por: Graf, Tilmann, et al.
Publicado: (2021)

Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany.
por: Thiele, Thomas, et al.
Publicado: (2021)

VITT REACTION ASSOCIATED WITH JOHNSON & JOHNSON COVID-19 VACCINE
por: AKUNA, MELANIE, et al.
Publicado: (2021)

Monoclonal and Oligoclonal Anti-PF4 Antibodies Mediate VITT
por: Singh, Bandana, et al.
Publicado: (2021)

Antiplatelet drugs block platelet activation by VITT patient serum
por: Smith, Christopher W., et al.
Publicado: (2021)

Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein
por: Greinacher, Andreas, et al.
Publicado: (2021)

Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin
por: Singh, B, et al.
Publicado: (2021)

Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient
por: Schönborn, Linda, et al.
Publicado: (2022)

Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT
por: Myllylahti, Lasse, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qsfvqlo2saimg41e271a5a9jq2